Elevated apolipoprotein B predicts poor postsurgery prognosis in patients with hepatocellular carcinoma
Open Access
- 1 March 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. ume 12, 1957-1964
- https://doi.org/10.2147/ott.s192631
Abstract
Aims: To date, curative resection remains to be the most optimal therapeutic choice of hepatocellular carcinoma (HCC), though the overall survival (OS) remains extremely unsatisfactory. To better manage the HCC patients, we evaluated the prognosis predicting values of apolipoprotein B (ApoB) and low-density lipoprotein cholesterol (LDL-C) on the long-time survival of patients who underwent surgical treatment in this study. Methods: A subgroup of 164 patients from our previously described follow-up cohort were enrolled in this study, of whom the pre-surgery ApoB and LDL-C measurements were available. They had been followed until January 2017, with a 19.5 months median survival time. The prognosis predicting values of serum ApoB, LDL-C, and other clinical variables were evaluated through Cox univariate and multivariate analyses, meanwhile, Kaplan–Meier analysis was conducted to obtain the OS curves. Results: Pre-surgery ApoB was an independent prognosis predicting factor with HR as 1.396 (P=0.033), elevated ApoB was associated with worse postsurgery prognosis in HCC patients. Concordantly, Spearman’s correlation analysis revealed that value of pre-surgery ApoB was to some extent correlated with tumor size (r=0.355, PP=0.004). Additionally, level of ApoB was found to be highly correlated with the serum level of LDL-C (r=0.686, PConclusion: ApoB could be a valuable novel prognosis predicting marker for HCC patients who underwent curative liver resection. Moreover, elevated ApoB level could indicate worse outcome in HCC patients, which could be explained by the relationship between ApoB and residual liver function.Keywords
This publication has 25 references indexed in Scilit:
- Predictability of Liver-Related Seromarkers for the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B PatientsPLOS ONE, 2013
- Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic TargetThe International Journal of Cell Cloning, 2012
- Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesisInternational Journal of Cancer, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- Dysregulation of the mevalonate pathway promotes transformationProceedings of the National Academy of Sciences of the United States of America, 2010
- Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancersGynecologic Oncology, 2010
- MicroRNA Expression, Survival, and Response to Interferon in Liver CancerThe New England Journal of Medicine, 2009
- The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and ProliferationCell Metabolism, 2008
- The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidenceJournal of Internal Medicine, 2006
- Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosisJournal of Internal Medicine, 2005